Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma

NCT04543071 is registered in ClinicalTrials.gov with Columbia University as lead sponsor.

NCT NCT04543071
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04543071 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study With Combination Chemotherapy (Gemcitabine and Nab-Paclitaxel), Chemokine (C-X-C) Motif Receptor 4 Inhibitor (BL-8040), and Immune Checkpoint Blockade (Cemiplimab) in METastatic Treatment naïve PANCreas Adenocarcinoma
Lead sponsor
Columbia University
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 9, 2020
Completion date
August 31, 2028
Enrollment
118 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, adenocarcinoma of the pancreas, pancreatic cancer